When LV function normalises in patients with takotsubo cardiomyopathy after one month, it could be considered to stop the ACE inhibitor and mineralocorticoid-receptor antagonist to avoid adverse events associated with these drugs [31]. This evidence concerns the gene NR3C2 and Tako-tsubo cardiomyopathy.